LISTING OF THE CLAIMS AS AMENDED

Please add new claims 107-142 so that the pending claims are as indicated in the following, complete listing of all claims ever presented in this application:

1-79. (Canceled).

80. (Previously presented) A sustained-release dosage form, comprising oxymorphone or a salt thereof, a hydrophilic polymer, a binder, and a diluent.

81. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form contains granules having a diameter from about 0.1 mm to about 3 mm.

82. (Previously presented) The sustained-release dosage form of claim 80, further comprising an alkylcellulose.

83. (Previously presented) The sustained-release dosage form of claim 80, further comprising ethylcellulose.

84. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a tablet.

85. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a capsule.

86. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form is in the form of a matrix.

87. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

88. (Previously presented) The sustained-release dosage form of claim 80, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

89. (Previously presented) A sustained-release dosage form, made by the process comprising: (a) mixing oxymorpbone or a salt thereof with a hyrodrophilic polymer, a binder, and a diluent; (b) subjecting the mixture to shear to form granules; and (c) incorporating the granules into a dosage form.

90. (Previously presented) The process of claim 89, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

91. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a tablet.

92. (Previously presented) The process of claim 89, wherein step (c) comprises incorporating the granules into a capsule.

93. (Previously presented) The process of claim 89, wherein the dosage form is a matrix.

94. (Previously presented) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with an alkylcellulose.

95. (Previously presented) The process of claim 89, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

96. (Previously presented) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

97. (Previously presented) The process of claim 89, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

98. (Previously presented) A process of making a sustained-release dosage form comprising: (a) mixing oxymorphone or a salt thereof with a hydrophilic polymer, a binder, and a diluent: (b) subjecting the mixture to shear to form granules; and (c) incorporating the granules into a dosage form.

99. (Previously presented) The process of claim 98, wherein the granules have a diameter from about 0.1 mm to about 3mm.

100. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a tablet.

101. (Previously presented) The process of claim 98, wherein step (c) comprises incorporating the granules into a capsule.

102. (Previously presented) The process of claim 98, wherein the dosage form is a matrix.

103. (Previously presented) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with alkylcellulose.

104. (Previously presented) The process of claim 98, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

105. (Previously presented) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

106. (Previously presented) The process of claim 98, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

107. (new) A sustained release oral analgesic dosage form comprising a unit dose of an effective amount of oxymorphone or salt thereof; and a plurality of pharmaceutically acceptable substrates, said substrates comprise a sustained release matrix material comprising a hydrophilic polymer, a hydrophobic polymer, a digestible long chain hydrocarbon, a polyalkylene glycol, or a mixture thereof.

108. (new) The sustained release dosage form of claim 107, wherein each of said substrates has a diameter of about 0.1 mm to about 3 mm.

109. (new) The sustained release dosage form of claim 108, wherein each of said substrates bas a diameter of about 0.5 mm to about 2 mm.

110. (new) The sustained release oral dosage form of claim 107, which comprises a substantially uniform mixture of said oxymorphone or salt thereof, and a hydrophobic polymer.

111. (new) The sustained release oral dosage form of claim 107, which provides a peak plasma level of oxymorphone in vivo from 2 to 10 hours after administration.

112. (new) The sustained release oral dosage form of claim 111, which provides a peak plasma level of oxymorphone in vivo from 2 to 4 hours after administration.

113. (new) The sustained release oral dosage form of claim 107, wherein said hydrophilic polymer comprises a gum, a cellulose ether, an acrylic resin, a protein derived material, or a mixture thereof.

114. (new) The sustained release oral dosage form of claim 113, wherein said cellulose ether is a hydroxyalkylcellulose or a carboxyalkylcellulose.

115. (new) The sustained release oral dosage form of claim 114, wherein said hydroxyalkylcellulose is a hydroxypropylcellulose, a hydroxypropylmethylcellulose, or a hydroxyethyl cellulose.

116. (new) The sustained release oral dosage form of claim 107, wherein said digestible long chain hydrocarbon is a digestible substituted or unsubstituted hydrocarbon having from about 8 to about 50 carbon atoms.

117. (new) The sustained release oral dosage form of claim 107, which contains between 1% to 80% of at least one hydrophilic polymer or at least one hydrophobic polymer.

118. (new) The sustained release oral dosage form according to claim 107, wherein said sustained release matrix material further comprises a diluent.

119. (new) The sustained release oral dosage form of claim 107, wherein said sustained release matrix material further comprises a binder.

120. (new) The sustained release oral dosage form of claim 107, wherein said substrates comprise beads, spheroids, microspheres, seeds, pellets, ion-exchange resin beads, granules and mixtures thereof.

121. (new) The sustained release oral dosage form according to claim 107, wherein said unit dose is contained within a hard gelatin capsule for oral administration.

122. (new) The sustained release oral dosage form of claim 107, wherein said dosage form provides effective steady-state blood levels in a human patient for greater than 12 hours.

123. (new) The sustained release oral dosage form of claim 107, wherein said dosage form provides effective steady-state blood levels in a human patient for at least 24 hours.

124. (new) The sustained release oral dosage form of claim 107, further comprising an effective amount of oxymorphone or salt thereof in immediate release form.

125. (new) The sustained release dosage form of claim 107, wherein the dosage form is in the form of a tablet.

126. (new) The sustained-release dosage form of claim 107, wherein the dosage form is in the form of a capsule.

127. (new) The sustained-release dosage form of claim 107, wherein the dosage form is in the form of a matrix.

128. (new) A sustained release oral analgesic dosage form comprising a unit dose of an effective amount of oxymorphone or salt thereof; and a plurality of pharmaceutically acceptable substrates, said substrates comprise a sustained release matrix material comprising a hydrophilic polymer, a hydrophobic polymer, a digestible long chain hydrocarbon, a polyalkylene glycol or a mixture thereof, a binder, and a diluent.

129. (new) The sustained release dosage form of claim 128, wherein the dosage form comprises granules having a diameter from about 0.1 mm to 3 mm.

130. (new) The sustained-release dosage form of claim 128, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

131. (new) The sustained-release dosage form of claim 128, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

132. (new) A sustained release oral analgesic dosage form comprising a unit dose of an effective amount of oxymorphone or salt thereof; and a plurality of pharmaceutically acceptable substrates, said substrates comprise a sustained release matrix material comprising a gum, a cellulose ether, an acrylic resin, a protein-derived material, or a mixture thereof, a binder, and a diluent.

133. (new) The sustained release dosage form of claim 132, wherein the dosage form comprises granules having a diameter from about 0.1 mm to 3 mm.

134. (new) The sustained-release dosage form of claim 132, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

135. (new) The sustained-release dosage form of claim 132, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

136. (new) A process for making a sustained release oral analgesic dosage form comprising:

forming granules comprising at least one water soluble hydroxyalkyl cellulose and oxymorphone or a salt thereof; and

mixing the hydroxylalkyl cellulose containing granules with at least one aliphatic alcohol.

137. (new) The process of claim 136, wherein said granules have a diameter from about 0.1 mm to about 3 mm.

138. (new) The process of claim 136, further comprising the step of incorporating the granules into a tablet.

139. (new) The process of claim 136, further comprising the step of incorporating the granules into a capsule.

140. (new) The process of claim 136, wherein said dosage form is a matrix.

141. (new) The process of claim 136, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

142. (new) The process of claim 136, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

* * * * *